Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Verastem, Inc. (VSTM)

Verastem Posts Updated Corporate Deck; Q3 AVMAPKI Net Product Revenue $24 Million

Neutral Impact 2 of 5 other Written later

Verastem posted an updated corporate presentation on its website on November 5, 2026, furnished as Exhibit 99.1. The deck reports third-quarter net product revenue of $24 million for AVMAPKI FAKZYNJA CO-PACK, says demand held steady after significant second-quarter growth, and notes FDA priority review for a blister pack application with a February 7, 2027 PDUFA date.

Key points

  • Q3 net product revenue of $24 million, cited to the November 5, 2026 press release
  • Demand held steady after significant Q2 growth, per the presentation
  • Blister pack NDA accepted with Priority Review; PDUFA date February 7, 2027
  • RAMP 301 Phase 3 topline readout expected in mid-2027

The filing

CompanyVerastem, Inc. (VSTM)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:32 PM ET
Accession number0001104659-26-123386

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.